Stella Pharma (TSE:4888) LT-Debt-to-Total-Asset: 0.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4888 Stella Pharma Corp TSE:4888
74 GF Score
Price 円337.00
GF Value 円337.87
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Stella Pharma LT-Debt-to-Total-Asset?

Stella Pharma TSE:4888 +3.69% 74 LT-Debt-to-Total-Asset is 0.13 as of Mar. 2026. GuruFocus rates TSE:4888 with a GF Score™ of 74/100 and a GF Value™ of 円337.87 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Stella Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.13.

Stella Pharma's long-term debt to total assets ratio increased from Mar. 2025 (0.11) to Mar. 2026 (0.13). It may suggest that Stella Pharma is progressively becoming more dependent on debt to grow their business.

Stella Pharma  (TSE:4888) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Stella Pharma LT-Debt-to-Total-Asset Related Terms

Stella Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Stella Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stella Pharma LT-Debt-to-Total-Asset Chart

Stella Pharma Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.23 0.22 0.20 0.11 0.13

Stella Pharma Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.13 0.11 0.11 0.13
TSE:4888
74GF Score
Stella Pharma Corp TSE:4888
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stella Pharma LT-Debt-to-Total-Asset Calculation

Stella Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=588.5/4486.694
=0.13

Stella Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=588.5/4486.694
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.13 mean?
Stella Pharma (TSE:4888) has a LT-Debt-to-Total-Asset of 0.13 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Stella Pharma and its competitors.
Is Stella Pharma's LT-Debt-to-Total-Asset too high?
Stella Pharma's current LT-Debt-to-Total-Asset is 0.13. Overall, Stella Pharma has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Stella Pharma's LT-Debt-to-Total-Asset of 0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Stella Pharma and its competitors. Stella Pharma's current LT-Debt-to-Total-Asset is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円337.87, compared to a current price of 円337.00 — trading 0.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.13. Stella Pharma's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current LT-Debt-to-Total-Asset is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stella Pharma (TSE:4888) Overvalued in 2026?

Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued. The current stock price of 円337.00 is trading 0.3% below its estimated GF Value™ of 円337.87. GuruFocus considers Stella Pharma to be Fairly Valued.

Key valuation signals for TSE:4888:

  • LT-Debt-to-Total-Asset: 0.13
  • GF Value™: 円337.87 vs. price of 円337.00 (0.3% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stella Pharma Business Description

Address 3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
74GF Score

Get the complete analysis for TSE:4888

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円337.00
Price
円337.87
GF Value